StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) stock

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $34.04MP/E –Yield –

Kalaris Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Kalaris Therapeutics's total assets was $99.54M at Jun 30, 2026. For fiscal 2025 it was $121.74M, up 1875.6% from the year before. The highest annual figure on record is $370.82M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$121.74M+1875.6%
FY2024Dec 31, 2024$6.16M-96.8%
FY2023Dec 31, 2023$190.80M-31.1%
FY2022Dec 31, 2022$277.08M-3.3%
FY2021Dec 31, 2021$286.59M-22.7%
FY2020Dec 31, 2020$370.82M+166.0%
FY2019Dec 31, 2019$139.42M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$99.54M+7.2%
Q1 FY2026Mar 31, 2026$109.81M+6.5%
Q4 FY2025Dec 31, 2025$121.74M+1875.6%
Q3 FY2025Sep 30, 2025$81.18M-33.8%
Q2 FY2025Jun 30, 2025$92.84M-29.1%
Q1 FY2025Mar 31, 2025$103.09M-28.5%
Q4 FY2024Dec 31, 2024$6.16M-96.8%
Q3 FY2024Sep 30, 2024$122.53M-50.7%
Q2 FY2024Jun 30, 2024$130.99M-53.7%
Q1 FY2024Mar 31, 2024$144.14M-40.9%
Q4 FY2023Dec 31, 2023$190.80M-31.1%
Q3 FY2023Sep 30, 2023$248.31M-15.5%
Q2 FY2023Jun 30, 2023$282.69M+41.3%
Q1 FY2023Mar 31, 2023$244.04M+5.6%
Q4 FY2022Dec 31, 2022$277.08M-3.3%
Q3 FY2022Sep 30, 2022$293.70M-7.2%
Q2 FY2022Jun 30, 2022$200.00M-38.9%
Q1 FY2022Mar 31, 2022$231.09M-34.2%
Q4 FY2021Dec 31, 2021$286.59M-22.7%
Q3 FY2021Sep 30, 2021$316.53M-19.6%
Q2 FY2021Jun 30, 2021$327.51M+177.9%
Q1 FY2021Mar 31, 2021$351.28M+152.0%
Q4 FY2020Dec 31, 2020$370.82M–
Q3 FY2020Sep 30, 2020$393.71M–
Q2 FY2020Jun 30, 2020$117.85M–
Q4 FY2019Dec 31, 2019$139.42M–

More Kalaris Therapeutics figures

See a number that looks wrong?